TNF-inhibitors in Wegener's granulomatosis.
Lamprecht
Peter
P
Voswinkel
Jan
J
Gross
Wolfgang L
WL
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D006801:Humans; D000069285:Infliximab; D011020:Pneumonia, Pneumocystis / Q000209:etiology / Q000401:mortality; D012307:Risk Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab